Molecular demand, sample limits

Cancer testing is moving toward smaller samples and bigger readouts, putting new pressure on how cytology specimens are collected, split, and stored. (ogt.com) Cytology is the lab work done on cells taken by fine-needle aspiration, body fluids, or smears instead of larger tissue biopsies. Reviews in *Cancer Cytopathology* and *Diagnostic Cytopathology* say those specimens can support molecular testing, but success depends on preanalytic steps such as fixation, tumor-cell count, and how material is triaged at the start. (acsjournals.onlinelibrary.wiley.com, pmc.ncbi.nlm.nih.gov) Next-generation sequencing is a broad DNA and RNA readout that can replace multiple single-gene tests with one panel. Oxford Gene Technology says its new white paper describes a custom SureSeq panel built with Kingston Health Sciences Centre for combined myeloid and lymphoid neoplasm analysis in a single assay. (ogt.com, ogt.com) OGT says the panel was designed to capture multiple classes of genomic drivers across blood cancers, including small sequence changes and larger structural events. The company’s SureSeq product page says the platform is built to detect low-frequency single-nucleotide variants, insertions and deletions, copy-number changes, loss of heterozygosity, and translocations. (ogt.com, ogt.com) A separate line of work is widening the ask on the same specimens. Spatial transcriptomics maps gene activity back onto its location in tissue, letting researchers see which cells are active and where they sit relative to tumor, immune, and stromal neighborhoods. (pmc.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov) Reviews of spatial transcriptomics say the method is being used to measure tumor heterogeneity, the patchwork of different cancer-cell and microenvironment states inside one lesion. Nature Communications and recent reviews describe spatial analyses that separate clone-specific patterns and local immune or stromal niches that bulk sequencing can blur together. (nature.com, pmc.ncbi.nlm.nih.gov) That combination creates a practical lab problem: one needle pass may need to cover diagnosis, immunostains, DNA testing, RNA testing, and now spatial assays. *Cancer Cytopathology* reviews say any cytology preparation can be usable for molecular work, but the deciding factor is often whether enough well-preserved tumor cells were set aside before the sample was exhausted. (acsjournals.onlinelibrary.wiley.com, acsjournals.onlinelibrary.wiley.com) The tradeoffs start before sequencing. Reviews say formalin-free cytology preparations can preserve higher-quality DNA and RNA than some formalin-fixed blocks, but different substrates—smears, cell blocks, cytospins, and residual fluids—do not perform the same way for every assay. (pubmed.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov) Several studies have linked adequacy checks at collection to better downstream testing. One precision-oncology study said rapid on-site evaluation helped identify inadequate procedures in real time and showed that concurrent cytology specimens with adequate cellularity could serve as a surrogate for biopsy material for next-generation sequencing. (pubmed.ncbi.nlm.nih.gov) Labs have also reported that the “best” slide for routine diagnosis is not always the best slide to consume for genomics. A 2020 study from MD Anderson found cytology smears improved success rates for RNA-based fusion testing compared with relying only on cell blocks, underscoring why specimen triage now starts at the microscope, not after the diagnosis is signed out. (pmc.ncbi.nlm.nih.gov) As molecular menus widen, the limiting reagent is often not the sequencer but the sample. The new panel work in hematologic neoplasms and the push toward spatial readouts both point to the same operational fact: a tiny cytology specimen now has to do much more than confirm that cancer is present. (ogt.com, pmc.ncbi.nlm.nih.gov)